Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic fecal microbiota (First Saint Petersburg State Medical University)
- Development stage
- Unknown
- Lead developer
- MaaT Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Allogeneic fecal microbiota (St. Petersburg State Pavlov Medical University) is a live biotherapeutic product consisting of encapsulated fecal matter derived from healthy donors. Developed by the St. Petersburg State Pavlov Medical University, it is designed to treat severe acute intestinal graft-versus-host disease (aGVHD), a frequent and severe complication of allogeneic hematopoietic stem cell transplantation. The therapy aims to restore the diversity of the intestinal microbiome, which is typically depleted in GVHD patients, thereby promoting intestinal barrier integrity and modulating the immune system to reduce systemic inflammation. In clinical trials, it is being evaluated as a first-line combination therapy alongside the JAK1/2 inhibitor ruxolitinib and corticosteroids to improve response rates in patients with severe intestinal involvement.
- Other names
- Fecal microbiota transplantationFMTallogeneic fecal microbiota
Beyond the preview
Go deeper on allogeneic fecal microbiota (First Saint Petersburg State Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic fecal microbiota (First Saint Petersburg State Medical University).